Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2025 04:00 ET | Source: Theolytics

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical...
October 07, 2025 03:00 ET | Source: Theolytics

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260THEO-260, is currently being investigated in patients with platinum-resistant ovarian...
December 17, 2024 03:00 ET | Source: Theolytics

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology, joins TheolyticsDr Apelian joins as the company advances its...
November 19, 2024 03:00 ET | Source: Theolytics

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours.Suitable for...
September 02, 2024 03:00 ET | Source: Theolytics

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic...
April 17, 2024 03:00 ET | Source: Theolytics

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a...